RT Journal Article
SR Electronic
T1 How to use nesiritide in treating decompensated heart failure
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 252
OP 256
VO 69
IS 3
A1 Mills, Roger M.
A1 Hobbs, Robert E.
YR 2002
UL http://www.ccjm.org/content/69/3/252.abstract
AB Nesiritide (Natrecor), a synthetic formulation of B-type natriuretic peptide (BNP), is the first new parenteral agent to be approved for treating heart failure in more than a decade. In patients hospitalized with decompensated congestive heart failure, nesiritide promptly reduces pulmonary capillary wedge pressure, pulmonary arterial pressure, right atrial pressure, and systemic vascular resistance, resulting in clinical improvement.